Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AiCuris and Hybridize close licensing deal related to BK virus program

By Brian Buntz | February 10, 2022

AiCuris-HybridizeBayer spin-off AiCuris (Wuppertal, Germany) has acquired exclusive rights to develop and commercialize RNA-based therapies for individuals with acute and chronic kidney diseases.

AiCuris will acquire the developmental therapies from the startup Hybridize Therapeutics (Leiden, Netherlands), which will get €100 million in upfront and milestone payments in addition to tiered royalties on net sales.

Sitting on Hybridize’s board of directors is Dr. John Maraganore, CEO of Alnylam Pharmaceuticals (NSDQ:ALNY).

At the heart of AiCuris’s licensing deal is an RNA-based antisense program for preventing BK virus infections in immunocompromised patients.

AiCuris will partner with Hybridize on preclinical development. AiCuris will take the lead on clinical development, which it anticipates will begin in two years.

RNA ASO MoA

RNA antisense oligonucleotides mode of action. Image courtesy of Hybridize.  

Reactivation of the BK virus (BKV) remains a significant challenge for patients undergoing kidney transplantation and can lead to a progressive graft dysfunction referred to as BK virus nephropathy (BKVN). BKNV can lead to allograft loss in kidney transplant recipients.

“We are excited to gain the rights to this exciting RNA-based antisense approach against BKV infections, further strengthening our anti-infective pipeline and building on our strong track record in the field of infectious diseases in transplant patients,” said Dr. Holger Zimmermann, CEO of AiCuris, in a news release.

 


Filed Under: clinical trials, Drug Discovery
Tagged With: AiCuris, Hybridize Therapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50